Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0LV7U
|
||||
| Former ID |
DNC007774
|
||||
| Drug Name |
1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528904] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H29N3O2
|
||||
| Canonical SMILES |
COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)CC4=CC=CC=C43
|
||||
| InChI |
1S/C23H29N3O2/c1-28-22-11-5-4-10-21(22)25-16-14-24(15-17-25)12-6-7-13-26-20-9-3-2-8-19(20)18-23(26)27/h2-5,8-11H,6-7,12-18H2,1H3
|
||||
| InChIKey |
VJMHUOSOEAGNQW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Inhibitor | [528904] | |
| D(1B) dopamine receptor | Target Info | Inhibitor | [528904] | ||
| D(2) dopamine receptor | Target Info | Inhibitor | [528904] | ||
| PANTHER Pathway | Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| GPCRs, OtherWP58:Monoamine GPCRs | |||||
| GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.